Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 04, 2020 08:30 ET | Source: Celsion CORP

Celsion Corporation to Continue Following Patients in Phase III OPTIMA Study for Overall Survival

Ongoing Analysis of Unblinded Study Data Suggests Data Maturity May be at Issue Cohort of 26 Consecutive Patient Deaths Differs Substantially from Predicted Behavior and from the Balance of the...
July 14, 2020 08:30 ET | Source: Celsion CORP

Celsion Corporation to Hold Conference Call to Discuss OPTIMA Study on Wednesday, July 15, 2020 at 11:00 a.m. Eastern Time

LAWRENCEVILLE, N.J., July 14, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) will host a conference call and webcast on Wednesday, July 15 at 11:00 a.m. Eastern time to discuss its...
March 03, 2020 08:30 ET | Source: Celsion CORP

Celsion CEO Issues Letter to Stockholders

LAWRENCEVILLE, N.J., March 03, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a leading oncology drug development company, announces that Michael H. Tardugno, the company’s chairman,...
November 14, 2019 08:00 ET | Source: Celsion CORP

Celsion Announces Publication of Research on Fluorescence Imaging of ThermoDox® Uptake in International Journal of Hyperthermia

Independent Analysis Confirms Increasing Heating Time + ThermoDox® Improves Tumor Uptake of Drug, which may be visualized by real-time fluorescence imaging Study Confirms that ThermoDox® Can Deliver...
August 14, 2019 16:30 ET | Source: Celsion CORP

Celsion Corporation Reports Second Quarter 2019 Financial Results and Provides Business Update

First Pre-Planned Efficacy Analysis of the Phase III OPTIMA Study Planned for Mid-October Strong Balance Sheet Plus the Non-Dilutive Sale of $4 Million of New Jersey State Net Operating...
August 05, 2019 09:00 ET | Source: Celsion CORP

Celsion Announces Data Lock for First Interim Analysis in OPTIMA Phase III Study of ThermoDox® in Primary Liver Cancer

Independent Data Monitoring Committee to Meet in October to Evaluate Interim Trial Data LAWRENCEVILLE, N.J., Aug. 05, 2019 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology...
July 10, 2018 08:00 ET | Source: Celsion CORP

CELSION ANNOUNCES PUBLICATION OF THERMODOX® PHASE I CLINICAL STUDY RESULTS IN THE LANCET ONCOLOGY

– The TARDOX Study, in Collaboration with University of Oxford, Evaluates the Use of Focused Ultrasound in Combination with ThermoDox® to Treat Primary and Metastatic Liver Cancer – – Imaging...